Impact of Baseline BCVA on Outcomes with Aflibercept 8 mg in Patients with DME

20260 citationsJournal Articlehybrid Open Access

Authors

Michael Javaheri · Retina Specialists

Priya S. Vakharia · Retina Vitreous Associates of Florida

Talia R. Kaden · Northwell Health

Sean D. Adrean · California Retina Consultants

Philip J. Ferrone · Vitreous Retina Macula Consultants of New York

Xiaomeng Niu · Regeneron (United States)

Jenfue Maa

Abstract

Aflibercept 8 mg demonstrated comparable visual and anatomic improvements versus 2 mg in patients with diabetic macular edema at week 96, regardless of baseline best-corrected visual acuity ≤20/50 versus ≥20/40.

Topics & Keywords

Medication Adherence and Compliance Rheumatoid Arthritis Research and Therapies Biosimilars and Bioanalytical Methods

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: Ophthalmology Retina

DOI: 10.1016/j.oret.2026.03.018

Field-Weighted Citation Impact: 0.00